Trump: 59% drop in US drug prices will end ‘global freeloading’
US President Donald Trump has signed an Executive Order calling for large cuts to the prices of drugs in the United States (US), to better match the prices paid by other countries.
The move has caused fluctuations in stock prices for pharmaceutical companies and is likely to significantly impact R&D budgets.
The order states that the US funds around three quarters of global pharmaceutical profits, claiming that “drug manufacturers deeply discount their products to access foreign markets, and subsidise that decrease through enormously high prices in the US”.
It adds that “the inflated prices in the US fuel global innovation while foreign health systems get a free ride” and that the Administration will take “aggressive action” against companies that fail to comply.
According to the order, within 30 days, the Secretary of Health and Human Services will communicate “most-favoured-nation price” targets to pharmaceutical manufacturers to bring prices for US patients in line with similar developed nations.
The document also states that, to the extent consistent with law, the Secretary of Health and Human Services shall facilitate direct-to-consumer purchasing programmes for pharmaceutical manufacturers that cut their prices for the US.
It also suggests the possibility of importing prescription drugs on a case-by-case basis from developed nations with lower prices.
According to Reuters, the executive order is likely to face legal challenges, particularly for exceeding limits set by US law, including on imports of drugs from abroad.
“The order’s suggestion of broader or direct-to-consumer importation stretches well beyond what the statute allows,” health policy lawyer Paul Kim told Reuters.
Diana Spencer, Senior Digital Content Editor, DDW
